Ubs Group Ag Catalyst Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 759,404 shares of CPRX stock, worth $16.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

759,404

Previous 722,858 5.06%

Holding current value

$16.5 Million

Previous $15.1 Million 22.07%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$19.53 - $25.74 $713,743 - $940,694	36,546 Added 5.06%	759,404 $18.4 Million
Q4 2024 Feb 14, 2025	BUY	$19.73 - $23.93 $10.1 Million - $12.2 Million	510,013 Added 239.62%	722,858 $15.1 Million
Q3 2024 Nov 14, 2024	BUY	$15.19 - $21.35 $660,066 - $927,742	43,454 Added 25.65%	212,845 $4.23 Million
Q2 2024 Aug 13, 2024	SELL	$14.68 - $16.92 $3.23 Million - $3.72 Million	-219,708 Reduced 56.47%	169,391 $2.62 Million
Q1 2024 May 13, 2024	SELL	$13.18 - $17.11 $1.06 Million - $1.37 Million	-80,217 Reduced 17.09%	389,099 $6.2 Million
Q4 2023 Feb 09, 2024	BUY	$11.78 - $17.29 $1.51 Million - $2.22 Million	128,595 Added 37.74%	469,316 $7.89 Million
Q3 2023 Nov 09, 2023	SELL	$11.69 - $15.02 $196,438 - $252,396	-16,804 Reduced 4.7%	340,721 $3.98 Million
Q2 2023 Aug 11, 2023	SELL	$11.5 - $18.08 $346,667 - $545,021	-30,145 Reduced 7.78%	357,525 $4.81 Million
Q1 2023 May 12, 2023	SELL	$14.34 - $21.05 $2.91 Million - $4.26 Million	-202,612 Reduced 34.32%	387,670 $6.43 Million
Q4 2022 Feb 08, 2023	BUY	$12.25 - $19.5 $3.2 Million - $5.09 Million	261,239 Added 79.39%	590,282 $11 Million
Q3 2022 Nov 10, 2022	BUY	$7.06 - $15.52 $28,458 - $62,561	4,031 Added 1.24%	329,043 $4.22 Million
Q2 2022 Aug 10, 2022	BUY	$6.23 - $8.57 $65,396 - $89,959	10,497 Added 3.34%	325,012 $2.28 Million
Q1 2022 May 16, 2022	BUY	$5.31 - $8.31 $131,942 - $206,486	24,848 Added 8.58%	314,515 $2.61 Million
Q4 2021 Feb 14, 2022	SELL	$5.21 - $7.45 $798,416 - $1.14 Million	-153,247 Reduced 34.6%	289,667 $1.96 Million
Q3 2021 Nov 15, 2021	BUY	$4.85 - $6.04 $224,327 - $279,368	46,253 Added 11.66%	442,914 $2.35 Million
Q2 2021 Aug 13, 2021	SELL	$4.29 - $6.05 $696,399 - $982,102	-162,331 Reduced 29.04%	396,661 $2.28 Million
Q1 2021 May 12, 2021	BUY	$3.45 - $4.69 $791,433 - $1.08 Million	229,401 Added 69.6%	558,992 $2.58 Million
Q4 2020 Feb 11, 2021	BUY	$2.97 - $3.83 $159,610 - $205,828	53,741 Added 19.48%	329,591 $1.1 Million
Q3 2020 Nov 12, 2020	BUY	$2.97 - $5.08 $819,274 - $1.4 Million	275,850 New	275,850 $819,000
Q2 2020 Jul 31, 2020	SELL	$3.48 - $5.05 $7,917 - $11,488	-2,275 Closed	0 $0
Q1 2020 May 01, 2020	SELL	$2.61 - $5.21 $41,499 - $82,839	-15,900 Reduced 87.48%	2,275 $9,000
Q4 2019 Feb 14, 2020	SELL	$3.67 - $5.7 $764,479 - $1.19 Million	-208,305 Reduced 91.98%	18,175 $68,000
Q3 2019 Nov 14, 2019	BUY	$3.89 - $7.43 $794,415 - $1.52 Million	204,220 Added 917.43%	226,480 $1.2 Million
Q2 2019 Aug 14, 2019	BUY	$2.7 - $6.11 $60,102 - $136,008	22,260 New	22,260 $85,000
Q1 2019 May 14, 2019	SELL	$2.11 - $5.33 $75,561 - $190,872	-35,811 Closed	0 $0
Q4 2018 Feb 14, 2019	BUY	$1.92 - $3.62 $24,076 - $45,394	12,540 Added 53.89%	35,811 $69,000
Q3 2018 Nov 14, 2018	BUY	$2.81 - $3.78 $31,115 - $41,855	11,073 Added 90.78%	23,271 $88,000
Q2 2018 Aug 14, 2018	BUY	$2.26 - $3.84 $27,567 - $46,840	12,198 New	12,198 $38,000
Q1 2018 May 15, 2018	SELL	$2.39 - $4.01 $25,580 - $42,919	-10,703 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$2.51 - $4.4 $20,830 - $36,515	8,299 Added 345.22%	10,703 $42,000
Q3 2017 Nov 14, 2017	SELL	$2.4 - $2.94 $8,738 - $10,704	-3,641 Reduced 60.23%	2,404 $6,000
Q2 2017 Aug 14, 2017	BUY	N/A	6,045	6,045 $17,000

Others Institutions Holding CPRX

# of Institutions

390

Shares Held

99.9M

Call Options Held

37K

Put Options Held

20.5K

View Full List

About CATALYST PHARMACEUTICALS, INC.

Ticker CPRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 102,820,000
Market Cap $2.23B
Description
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...

More about CPRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account